Brighter AB (Publ.) announced that the company has signed a Memorandum of Understanding (MOU) with Emirates Health Services (EHS) in the United Arab Emirates (UAE) with the intention to jointly roll out an Actiste® user experience study. The user experience study is expected to involve up to one hundred clinically diagnosed type 2 diabetes patients in the area and the patients will use the Actiste Diabetes Management as a Service (ADMS) for a period of 90 days. The primary aim of the user study is to confirm the positive user experience of patients and their healthcare providers.

The company also looks forward to discussing the subsequent nationwide roll-out of ADMS in the UAE with EHS. Patients enrolled in the user study will undergo home monitoring. Each patient will respond to a questionnaire at the commencement and completion of the Pilot Project to evaluate their experience of ADMS. The goal of the evaluation process is to assess ADMS when compared to each Patient's conventional diabetes management.

In addition, primary healthcare centers and their staff will complete corresponding questionnaires to determine their experience with ADMS. The user study will be ready to start once the final project design has been agreed on by both parties.